PET Imaging Study for HER2-Positive Breast Cancer
Part of Cancer, Skin clinical trials.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have breast cancer that is known or suspected to have HER2 protein.
- You are in good enough health to have a life expectancy of at least 12 weeks.
- You have at least one tumor that can be measured on a scan.
- If you can have children, you must use effective birth control during the study and for 6 months after the last PET scan.
- You are willing to sign a consent form and follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent (18F-FAPI-04) for PET scans to see if it can better detect breast cancer or its spread. It may help doctors find tumors more clearly.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.